BCL-2抑制剂维奈克拉在白血病治疗中的研究进展

打开文本图片集

中图分类号：R733.7 文献标志码：A文章编号：1673-3851（2026）05-0324-10

Reference Format：ZHAO Xiaoxiao，LI Xinwei，LIN Jiabohao，etal.Progressof BCL-2 inhibitor venetoclax inthe treatment of leukemia[J]. Journal of Zhejiang Sci-Tech University，2O26，55（3） ：324-333.

Progress of BCL-2 inhibitor venetoclax in the treatment of leukemia

ZHAO Xiaoxiao，LI Xinwei ，LIN Jiabohao，JIN Juan （College of Life Sciences and Medicine， Zhejiang Sci-Tech University，Hangzhou 31ool8，China）

Abstract： Apoptosis resistance is a core biological characteristic driving the malignant progresson and therapeutic tolerance in leukemia，with its key molecular mechanism rooted in the aberrant overexpression of B-cell lymphoma-2 （BCL-2）. Highly selective BCL-2 inhibitors，exemplified by venetoclax，specifically reactivate the mitochondrial apoptosis pathway in tumor cells by mimicking conformational characteristics of BH3-only proteins，thereby exhibiting substantial efficacy in the treatment of various leukemia subtypes. Nevertheless， venetoclax monotherapy remains plagued by challenges， including limited remision rates and a high risk of acquired resistance.This article summarizes the critical role of the BCL-2 family in mediating apoptosis resistance in leukemia cells， highlights advances in research on the combination of venetoclax and other therapeutic drugs for leukemia treatment，and explores the challenges associated with BCL-2 targeted therapy in future clinical applications. The aim is to provide theoretical reference and practical evidence to optimize combination treatment strategies for leukemia.

Key Words： BCL-2；venetoclax; leukemia；drug resistance； combination therapy

0引言

以白血病为代表的血液系统恶性肿瘤具有较高的发病率与致死率，严重威胁全球公共健康，急性髓系白血病（Acutemyeloidleukemia，AML）、急性淋巴细胞白血病（Acutelymphoblasticleukemia，ALL）、慢性淋巴细胞白血病（Chroniclymphocyticleukemia，CLL）及慢性髓系白血病（Chronicmyeloidleukemia，CML）是白血病临床诊疗中最常见的4大亚型。（剩余22550字）